<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene T19R;E156del;F157del;R158G;L452R;T478K;D614G;P681R;D950 literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.T19R;E156_F157del;R158G;L452R;T478K;D614G;P681R;D950</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> L27, V34 and E90 mutation resulted in ultrahigh affinity binding of the LVE-ACE-2 domain to the widest variety of VOCs, with KDs of 507 pM for binding to the Delta  B.1.617.2. Values were obtained with LVE-ACE-2/mAB chimeras containing the Y-T-E sequence that enhances binding to the FcRn receptor, which in turn is expected to  extend biological half-life 3-4-fold.<br/> (<a href="https://doi.org/10.1101/2022.06.23.497326" class="lit_link">Uhal B et al. (2022)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Plasma neutralizing activity was also assessed against SARS-CoV-2 Delta, Omicron BA.1, BA.2 and BA.4/5 variants using viruses pseudotyped with appropriate  variant spikeproteins. Delta breakthrough infection resulted in 15-fold increased neutralizing titers.<br/> (<a href="https://doi.org/10.1101/2022.08.11.503601" class="lit_link">Wang et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Plasma neutralizing activity in 49 participants was measured using HIV-1 pseudotyped with the 100 WT SARS-CoV-2 spike protein. Delta breakthrough infection  resulted in 11-fold increased geometric mean half-maximal neutralizing titer (NT50).<br/> (<a href="https://doi.org/10.1101/2022.08.11.503601" class="lit_link">Wang et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Log10ID50 of Delta neutralizing antibodies is 0.872x the WT pre-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of  55.5.<br/> (<a href="https://doi.org/10.1101/2022.06.24.22276144" class="lit_link">McEvoy C et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Log10ID50 of Delta neutralizing antibodies is 0.952x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median  age of 55.5.<br/> (<a href="https://doi.org/10.1101/2022.06.24.22276144" class="lit_link">McEvoy C et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Paradigmâ€™s ACE-2 variant LVE/STR chimera neutralizes Delta Variant B.1.617.2 RBD or w.t. SARS-CoV-2 RBD with nearly equal potency determined using Surrogate Viral Neutralization Tests.<br/> (<a href="https://doi.org/10.1101/2022.06.23.497326" class="lit_link">Uhal B et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
